Synthesis, antibacterial and antitubercular activities of some 7-[4-(5-amino-[1,3,4]thiadiazole-2-sulfonyl)-piperazin-1-yl] fluoroquinolonic derivatives

被引:106
作者
Talath, S.
Gadad, A. K. [1 ]
机构
[1] JN Med Coll, Dept Med Chem, Coll Pharm, Belgaum 590010, Karnataka, India
[2] Univ W Indies Coll, Sch Pharm, Fac Med Sci, Champs Fleurs, Mt Hope, Trinidad Tobago
关键词
N-sulfonyl fluoroquinolones; 1,3,4-Thiadiazole; antibacterial activity; antinibercular activity; broth dilution assay method;
D O I
10.1016/j.ejmech.2006.03.027
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In the present study, a series of 7-[4-(5-amino-1,3,4 thiadiazole-2-sulfonyl)]-1-piperazinyl fluoroquinolonic derivatives VIIa-d were synthesized in good yields and characterized by IR, H-1-NMR, C-13-NMR, FAB Mass spectral and elemental analyses. The compounds were evaluated for their preliminary in vitro antibacterial activity against some Gram-positive and Gram-negative bacteria and selected compounds VIIa, b were screened for antitubercular activity against Mycobacterium tuberculosis H(37)Rv strain by broth dilution assay method. The antibacterial data of the tested N-sulfonylfluoroquinolones VIIa-d indicated that all the synthesized compounds showed better activity against Gram-positive bacteria S. aureus, E. faecelis, Bacillus sp. (MIC = 1-5 mu g ml(-1), respectively) compared to reference drugs. The MIC values of tested derivatives connotes that the sparfloxacin and gatifloxacin derivatives VIIc, d were most active against the tested Gram-positive bacterial strains (MIC = 1-5 mu g ml(-1)). All the tested compounds VIIa-d showed poor activity against the Gram-negative bacteria. The in vitro antitubercular activity reports of selected compounds VIIa, b against M tuberculosis strain H(37)Rv showed moderate activity at MIC of 10 mu g ml(-1). (c) 2006 Elsevier SAS. All rights reserved.
引用
收藏
页码:918 / 924
页数:7
相关论文
共 49 条
[1]   IN-VITRO ACTIVITY OF NEW SULPHANILIL FLUOROQUINOLONES AGAINST STAPHYLOCOCCUS-AUREUS [J].
ALLEMANDI, DA ;
ALOVERO, FL ;
MANZO, RH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 34 (02) :261-265
[2]   The future of the quinolones [J].
Andriole, VT .
DRUGS, 1999, 58 (Suppl 2) :1-5
[3]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[4]  
*CAMBR CORP, CHEMDR ULTR 6 0
[5]  
CROFTON J, 1997, GUIDELINES MANAGEMEN
[6]   NEW STRUCTURE-ACTIVITY-RELATIONSHIPS OF THE QUINOLONE ANTIBACTERIALS USING THE TARGET ENZYME - THE DEVELOPMENT AND APPLICATION OF A DNA GYRASE ASSAY [J].
DOMAGALA, JM ;
HANNA, LD ;
HEIFETZ, CL ;
HUTT, MP ;
MICH, TF ;
SANCHEZ, JP ;
SOLOMON, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (03) :394-404
[7]  
FAIRFIELD CT, 2002, IMS HLTH INCORPORATE
[8]   Synthesis, antibacterial, and cytotoxic evaluation of certain 7-substituted norfloxacin derivatives [J].
Fang, KC ;
Chen, YL ;
Sheu, JY ;
Wang, TC ;
Tzeng, CC .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) :3809-3812
[9]  
Foroumadi A, 2003, PHARMAZIE, V58, P432
[10]   Synthesis and in vitro antibacterial evaluation of N-[5-(5-vitro-2-thienyl)-1, 3,4-thiadiazole-2-yl] piperazinyl quinolones [J].
Foroumadi, A ;
Mansouri, S ;
Kiani, Z ;
Rahmani, A .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2003, 38 (09) :851-854